Oral Communication ▸ Antiviral treatment in COVID-19
Oral Communication ▸ Bench studies of viral infections
Oral Communication ▸ Body and mind
OC 119
OC 120
OC 121
OC 122
Oral Communication ▸ Cardiovascular and malignancies
Oral Communication ▸ Clinical approach to COVID in vulnerable populations
OC 139
OC 140
OC 141
OC 142
Oral Communication ▸ Clinical issues blinking to laboratory
Oral Communication ▸ Clinical outcome of SARS-CoV-2 infection
Oral Communication ▸ COVID-19 outcome in special population
Oral Communication ▸ Early treatment for COVID-19
Oral Communication ▸ Education and knowledge to reduce the burden of HIV and STIs
OC 111
OC 112
OC 113
OC 114
Oral Communication ▸ Emerging immunological and virological concepts in viral hepatitis
Oral Communication ▸ Emerging issues in HIV-1 infection
OC 143
OC 144
OC 145
OC 146
Oral Communication ▸ Epidemiology trends in infections
Oral Communication ▸ HIV: much left to do
Oral Communication ▸ Immune response in SARS-CoV-2
Oral Communication ▸ Immune response to viruses
Oral Communication ▸ Inflammation: a major pathogenetic process
Oral Communication ▸ Innovative tools for diagnosis and monitoring of viral infections
OC 99
OC 100
OC 101
OC 102
Oral Communication ▸ Liver, vessels and lipids
Oral Communication ▸ Mpox and Immunopathogenic mechanisms
OC 131
OC 132
OC 133
OC 134
Oral Communication ▸ Novel clinical and epidemiological aspects of viral hepatitis
OC 147
OC 148
OC 149
OC 150
Oral Communication ▸ One size does not fit all
Oral Communication ▸ Oral or injectable 2-drug regimens
Oral Communication ▸ Outcome in first-line regimens
Oral Communication ▸ Outcomes in treatment experienced PLWH
OC 135
OC 136
OC 137
OC 138
Oral Communication ▸ PACS: clinical outcome
OC 123
OC 124
OC 125
OC 126
Oral Communication ▸ PACS: what to asses
Oral Communication ▸ Preferences limitations and long term outcomes
Oral Communication ▸ Prevention, access and engagement
Oral Communication ▸ Real world evidence in different treatment setting
OC 115
OC 116
OC 117
OC 118
Oral Communication ▸ Severe clinical issues in HIV-1 infection
Oral Communication ▸ The experience of PrEP in Italy
OC 103
OC 104
OC 105
OC 106
Oral Communication ▸ The increasing burden of STIs
OC 73
OC 74
OC 75
OC 76
OC 77
Oral Communication ▸ Vaccine in frail patients
OC 78
OC 79
OC 80
OC 81
OC 82
Oral Communication ▸ Viral infections old and new
Oral Communication ▸ Virological topics in SARS-CoV-2 infection
OC 107
OC 108
OC 109
OC 110
Oral Communication ▸ Viruses, resistance and drugs
OC 127
OC 128
OC 129
OC 130
Poster ▸ Antiretroviral therapy
P 1
P 2
P 3
P 4
P 5
P 6
P 7
P 8
P 9
P 10
P 11
P 12
P 13
P 14
P 15
P 16
P 17
P 18
P 19
P 20
P 21
P 22
P 23
P 24
P 25
P 26
P 27
P 28
P 29
P 30
P 31
P 32
P 33
P 34
P 35
P 36
P 37
P 38
P 39
P 40
P 41
P 42
P 43
P 44
Poster ▸ Clinical HIV
P 45
P 46
P 47
P 48
P 49
P 50
P 51
P 52
P 53
P 54
P 55
P 56
P 57
P 58
P 59
P 60
P 61
P 62
P 63
P 64
P 65
P 66
P 67
P 68
P 69
P 70
P 71
P 72
P 73
P 74
P 75
P 76
P 77
Poster ▸ Comorbidities
P 78
P 79
P 80
P 81
P 82
P 83
P 84
P 85
P 86
P 87
P 88
P 89
P 90
P 91
P 92
P 93
P 94
P 95
P 96
P 97
P 98
P 99
P 100
P 101
P 102
P 103
P 104
P 105
P 106
P 107
P 108
P 109
Poster ▸ COVID-19
P 110
P 111
P 112
P 113
P 114
P 115
P 116
P 117
P 118
P 119
P 120
P 121
P 122
P 123
P 124
P 125
P 126
P 127
P 128
P 129
P 130
P 131
P 132
P 133
P 134
P 135
P 136
P 137
P 138
P 139
P 140
P 141
P 142
P 143
P 144
P 145
P 146
P 147
P 148
P 149
P 150
P 151
P 152
P 153
P 154
P 155
P 156
P 157
P 158
P 159
P 160
P 161
P 162
P 163
P 164
P 165
P 166
P 167
P 168
P 169
P 170
P 171
P 172
P 173
P 174
P 175
P 176
P 177
P 178
P 179
P 180
P 181
P 182
Poster ▸ Epidemiology and Prevention
P 183
P 184
P 185
P 186
P 187
P 188
P 189
P 190
P 191
P 192
P 193
P 194
P 195
P 196
P 197
P 198
P 199
P 200
P 201
P 202
P 203
Poster ▸ Hepatitis and other viral infections
P 204
P 205
P 206
P 207
P 208
P 209
P 210
P 211
P 212
P 213
P 214
P 215
P 216
P 217
P 218
P 219
P 220
P 221
P 222
P 223
P 224
P 225
P 226
P 227
Poster ▸ Immunopathogenesis and Vaccines
P 228
P 229
P 230
P 231
P 232
P 233
P 234
P 235
P 236
P 237
P 238
P 239
P 240
P 241
P 242
P 243
P 244
P 245
P 246
Poster ▸ PrEP
P 247
P 248
P 249
P 250
P 251
P 252
P 253
P 254
P 255
P 256
P 257
Poster ▸ Social and behavioural science, marginalized groups, community aspects and community surveys
P 258
P 259
P 260
P 261
P 262
P 263
P 264
P 265
P 266
P 267
P 268
P 269
P 270
P 271
P 272
P 273
P 274
P 275
P 276
P 277
P 278
P 279
P 280
P 281
P 282
P 283
P 284
P 285
P 286
P 287
P 288
P 289
P 290
P 291
P 292
P 293
P 294
P 295
P 296
Poster ▸ STIs, Sexually transmitted infections
P 297
P 298
P 299
P 300
P 301
P 302
P 303
P 304
P 305
P 306
P 307
P 308
P 309
P 310
P 311
P 312
P 313
P 314
P 315
Poster ▸ Virology and Pharmacology
P 316
P 317
P 318
P 319
P 320
P 321
P 322
P 323
P 324
P 325
P 326
P 327
P 328
P 329
P 330
P 331